Journal of the American Academy of Dermatology · 2026
Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Naik Haley B, Yeung Howa, Frazer-Green Lindsy, Daveluy Steven Daniel, Garg Amit, McMichael Amy J, Sayed Christopher John, Hightower George K, Okoye Ginette, Keeler Kelly, Orenstein Lauren A V, Plotke Melanie, Shive Melissa, Wu Peggy A, Burkhart Craig N
Аннотация
BACKGROUND: Hidradenitis suppurativa affects 0.7% to 1.5% of the global population and causes substantial disability and meaningfully impairs quality of life.
OBJECTIVE: To provide evidence-based recommendations for the management of hidradenitis suppurativa.
METHODS: A workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach to assess the certainty of evidence and to develop recommendations.
RESULTS: This guideline presents 37 evidence-based recommendations. Strong recommendations are made for adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Conditional recommendations are made for topical clindamycin, resorcinol, and ruxolitinib; oral doxycycline, tetracycline, and clindamycin with rifampin; intravenous ertapenem; spironolactone; short-term systemic corticosteroids; upadacitinib; specific procedural interventions; tobacco cessation; supportive pain management; and zinc supplementation and vitamin D repletion.
LIMITATIONS: Analysis is limited to best evidence available from systematic review.
CONCLUSIONS: These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa.
OBJECTIVE: To provide evidence-based recommendations for the management of hidradenitis suppurativa.
METHODS: A workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach to assess the certainty of evidence and to develop recommendations.
RESULTS: This guideline presents 37 evidence-based recommendations. Strong recommendations are made for adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Conditional recommendations are made for topical clindamycin, resorcinol, and ruxolitinib; oral doxycycline, tetracycline, and clindamycin with rifampin; intravenous ertapenem; spironolactone; short-term systemic corticosteroids; upadacitinib; specific procedural interventions; tobacco cessation; supportive pain management; and zinc supplementation and vitamin D repletion.
LIMITATIONS: Analysis is limited to best evidence available from systematic review.
CONCLUSIONS: These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa.